Cover Image
市場調查報告書

黑色素瘤:開發平台分析

Melanoma - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 232839
出版日期 內容資訊 英文 1479 Pages
訂單完成後即時交付
價格
Back to Top
黑色素瘤:開發平台分析 Melanoma - Pipeline Review, H1 2016
出版日期: 2016年06月30日 內容資訊: 英文 1479 Pages
簡介

所謂黑色素瘤,是黑色素細胞惡性轉換發展成腫瘤。這些細胞是來自神經嵴,黑色素瘤通常出現在皮膚上,不過是在神經嵴移行的地方譬如消化管和腦發生。女性比男性好發,尤其出現在女性的腳和男性的背部。皮膚上如果有是黑痣,痛的地方、塊、傷、花樣等明顯看到或感覺到的地方為黑色素瘤的前兆。治療方法有手術和放射線及質子治療等。

本報告提供黑色素瘤的治療藥開發平台的現狀及最新更新的各開發階段比較分析、企業和研究機關開發中的治療藥、治療藥的評估、後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

  • 黑色素瘤 概要

治療藥的開發

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

企業開發中的產品

大學/機關研究中的產品

開發治療藥的企業

治療藥的評估

藥物簡介

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7955IDB

Summary

Global Markets Direct's, 'Melanoma - Pipeline Review, H1 2016', provides an overview of the Melanoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Melanoma
  • The report reviews pipeline therapeutics for Melanoma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Melanoma therapeutics and enlists all their major and minor projects
  • The report assesses Melanoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Melanoma

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Melanoma
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Melanoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Melanoma Overview
  • Therapeutics Development
  • Melanoma - Therapeutics under Development by Companies
  • Melanoma - Therapeutics under Investigation by Universities/Institutes
  • Melanoma - Pipeline Products Glance
  • Melanoma - Products under Development by Companies
  • Melanoma - Products under Investigation by Universities/Institutes
  • Melanoma - Companies Involved in Therapeutics Development
  • Melanoma - Therapeutics Assessment
  • Drug Profiles
  • Melanoma - Dormant Projects
  • Melanoma - Discontinued Products
  • Melanoma - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Melanoma, H1 2016
  • Number of Products under Development for Melanoma - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Development by Companies, H1 2016 (Contd..8)
  • Number of Products under Development by Companies, H1 2016 (Contd..9)
  • Number of Products under Development by Companies, H1 2016 (Contd..10)
  • Number of Products under Development by Companies, H1 2016 (Contd..11)
  • Number of Products under Development by Companies, H1 2016 (Contd..12)
  • Number of Products under Development by Companies, H1 2016 (Contd..13)
  • Number of Products under Development by Companies, H1 2016 (Contd..14)
  • Number of Products under Development by Companies, H1 2016 (Contd..15)
  • Number of Products under Development by Companies, H1 2016 (Contd..16)
  • Number of Products under Development by Companies, H1 2016 (Contd..17)
  • Number of Products under Development by Companies, H1 2016 (Contd..18)
  • Number of Products under Development by Companies, H1 2016 (Contd..19)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..3)
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Development by Companies, H1 2016 (Contd..9)
  • Products under Development by Companies, H1 2016 (Contd..10)
  • Products under Development by Companies, H1 2016 (Contd..11)
  • Products under Development by Companies, H1 2016 (Contd..12)
  • Products under Development by Companies, H1 2016 (Contd..13)
  • Products under Development by Companies, H1 2016 (Contd..14)
  • Products under Development by Companies, H1 2016 (Contd..15)
  • Products under Development by Companies, H1 2016 (Contd..16)
  • Products under Development by Companies, H1 2016 (Contd..17)
  • Products under Development by Companies, H1 2016 (Contd..18)
  • Products under Development by Companies, H1 2016 (Contd..19)
  • Products under Development by Companies, H1 2016 (Contd..20)
  • Products under Development by Companies, H1 2016 (Contd..21)
  • Products under Development by Companies, H1 2016 (Contd..22)
  • Products under Development by Companies, H1 2016 (Contd..23)
  • Products under Development by Companies, H1 2016 (Contd..24)
  • Products under Development by Companies, H1 2016 (Contd..25)
  • Products under Development by Companies, H1 2016 (Contd..26)
  • Products under Development by Companies, H1 2016 (Contd..27)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..5)
  • Melanoma - Pipeline by 4SC AG, H1 2016
  • Melanoma - Pipeline by AB Science SA, H1 2016
  • Melanoma - Pipeline by AbbVie Inc., H1 2016
  • Melanoma - Pipeline by ACF Pharmaceuticals, LLC, H1 2016
  • Melanoma - Pipeline by Adamis Pharmaceuticals Corporation, H1 2016
  • Melanoma - Pipeline by Adaptimmune Therapeutics Plc, H1 2016
  • Melanoma - Pipeline by Adicet Bio, Inc., H1 2016
  • Melanoma - Pipeline by Aduro BioTech, Inc., H1 2016
  • Melanoma - Pipeline by Advaxis, Inc., H1 2016
  • Melanoma - Pipeline by Aeterna Zentaris Inc., H1 2016
  • Melanoma - Pipeline by Affichem SA, H1 2016
  • Melanoma - Pipeline by Agalimmune Ltd, H1 2016
  • Melanoma - Pipeline by Agenus, Inc., H1 2016
  • Melanoma - Pipeline by Agilvax, Inc., H1 2016
  • Melanoma - Pipeline by AGV Discovery, SAS, H1 2016
  • Melanoma - Pipeline by AIMM Therapeutics B.V., H1 2016
  • Melanoma - Pipeline by Alethia Biotherapeutics Inc., H1 2016
  • Melanoma - Pipeline by Altor BioScience Corporation, H1 2016
  • Melanoma - Pipeline by Amgen Inc., H1 2016
  • Melanoma - Pipeline by Anavex Life Sciences Corp., H1 2016
  • Melanoma - Pipeline by Angimmune LLC, H1 2016
  • Melanoma - Pipeline by Antibe Therapeutics, Inc., H1 2016
  • Melanoma - Pipeline by Antigen Express, Inc., H1 2016
  • Melanoma - Pipeline by APEIRON Biologics AG, H1 2016
  • Melanoma - Pipeline by Apexigen, Inc., H1 2016
  • Melanoma - Pipeline by Aphios Corporation, H1 2016
  • Melanoma - Pipeline by APO-T B.V., H1 2016
  • Melanoma - Pipeline by Apogenix GmbH, H1 2016
  • Melanoma - Pipeline by Aposense Ltd., H1 2016
  • Melanoma - Pipeline by Aptose Biosciences Inc., H1 2016
  • Melanoma - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2016
  • Melanoma - Pipeline by Array BioPharma Inc., H1 2016
  • Melanoma - Pipeline by Asana BioSciences, LLC, H1 2016
  • Melanoma - Pipeline by Astex Pharmaceuticals, Inc., H1 2016
  • Melanoma - Pipeline by AstraZeneca Plc, H1 2016
  • Melanoma - Pipeline by Aurigene Discovery Technologies Limited, H1 2016
  • Melanoma - Pipeline by Azaya Therapeutics, Inc., H1 2016
  • Melanoma - Pipeline by Basilea Pharmaceutica AG, H1 2016
  • Melanoma - Pipeline by Batu Biologics, Inc., H1 2016
  • Melanoma - Pipeline by Bayer AG, H1 2016
  • Melanoma - Pipeline by BeiGene, Ltd., H1 2016
  • Melanoma - Pipeline by Beijing Kawin Technology Share-Holding Co., Ltd., H1 2016
  • Melanoma - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016
  • Melanoma - Pipeline by Bio-Cancer Treatment International Limited, H1 2016
  • Melanoma - Pipeline by BioApex, s.r.o., H1 2016
  • Melanoma - Pipeline by BIOCAD, H1 2016
  • Melanoma - Pipeline by Biogazelle, H1 2016
  • Melanoma - Pipeline by Biogenomics Limited, H1 2016
  • Melanoma - Pipeline by BioLineRx, Ltd., H1 2016
  • Melanoma - Pipeline by Bioncotech Therapeutics S.L., H1 2016
  • Melanoma - Pipeline by Bionomics Limited, H1 2016
  • Melanoma - Pipeline by BioNTech AG, H1 2016
  • Melanoma - Pipeline by Bioo Therapeutics, H1 2016
  • Melanoma - Pipeline by Biovista Inc., H1 2016
  • Melanoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Melanoma - Pipeline by Boston Biomedical, Inc., H1 2016
  • Melanoma - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Melanoma - Pipeline by Calithera Biosciences, Inc., H1 2016
  • Melanoma - Pipeline by Can-Fite BioPharma Ltd., H1 2016
  • Melanoma - Pipeline by CCRP Therapeutics GmbH, H1 2016
  • Melanoma - Pipeline by Cellceutix Corporation, H1 2016
  • Melanoma - Pipeline by Celldex Therapeutics, Inc., H1 2016
  • Melanoma - Pipeline by Celprogen, Inc., H1 2016
  • Melanoma - Pipeline by Celyad SA, H1 2016
  • Melanoma - Pipeline by Chipscreen Biosciences Ltd, H1 2016
  • Melanoma - Pipeline by Cipher Pharmaceuticals Inc., H1 2016

List of Figures

  • Number of Products under Development for Melanoma, H1 2016
  • Number of Products under Development for Melanoma - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top